# V1 Empirics Check — openai/gpt-5.4 (Variant C)

**Model:** openai/gpt-5.4
**Variant:** C
**Date:** 2026-03-25T16:29:07.993470

---

## 1. Idea Fidelity

The paper only partially pursues the original idea in the manifest, and in some important ways it drifts away from the strongest version of that design.

First, the manifest’s core outcomes were **NPRM-to-final duration, completion within four years, and withdrawal**, with the EO 13771 designation ratio as a secondary composition outcome. The paper instead centers on **monthly counts of NPRMs, final rules, and total rulemaking volume**, and duration becomes a null side result. That is a meaningful pivot in research question: the paper is no longer mainly about whether the regulatory budget changed the *speed and completion* of rulemaking, but whether it changed *counts*. That can still be interesting, but it is not the original design, and the paper does not explain why the original outcomes were abandoned.

Second, the manifest proposed a broad sample of agencies/dockets and suggested **agency-semester aggregation** with a reversal test around 2021. The paper narrows to **23 agencies with at least 50 dockets**, balanced monthly panel, without convincing justification for this sample restriction. Given that identification comes from cross-agency treatment intensity, sample selection among agencies matters a lot. Excluding many smaller agencies may alter both treatment variation and political comparability.

Third, the manifest’s sharpest test of mechanism was the distinction between **protective vs deregulatory rules** using the EO 13771 designation field. Yet the paper’s headline claim—“EO 13771 increased total rulemaking activity by incentivizing the finalization of deregulatory actions”—is not directly demonstrated with designation-coded outcomes. That is the most natural test of the mechanism, and omitting it is a missed opportunity. In short: the paper uses the same institutional setting and treatment-intensity idea, but it does not execute the most compelling version of the original empirical design.

## 2. Summary

This paper studies whether EO 13771’s “two-for-one” regulatory budget differentially affected agencies with higher pre-2017 shares of economically significant rules. Using Regulations.gov data, it reports that high-intensity agencies saw weakly lower NPRM activity, somewhat higher final-rule counts, and a small increase in total rulemaking during the EO period, with suggestive persistence in lower NPRM activity after rescission.

The topic is important and the setting is potentially valuable. But in its current form, the paper does not yet deliver a clear, well-identified, economically meaningful result. The main estimates are fragile, the interpretation outruns the evidence, and the strongest mechanism tests are absent.

## 3. Essential Points

1. **The paper’s headline result is not clearly identified or economically persuasive.**  
   The central estimate is a coefficient of 0.380 on log total rulemaking, significant only at the 10 percent level, with very weak and noisy component estimates for NPRMs and final rules. It is hard to build a strong “deregulatory dividend” claim from a pattern where the increase in total volume is marginal, the increase in final rules is insignificant, and the decline in NPRMs is near zero in the main specification. More importantly, because treatment intensity ranges from near 0 to about 0.59, the implied effect for realistic agency comparisons is modest and needs to be translated properly. For example, a 0.38 coefficient per unit of intensity does **not** mean a 38 percent increase for a typical high-intensity agency; for an interquartile treatment difference, the implied effect may be much smaller. The paper repeatedly speaks in large substantive terms without presenting those implied magnitudes cleanly.

2. **Inference is not yet convincing given only 23 clusters and substantial serial dependence.**  
   Agency-clustered standard errors with 23 clusters are borderline; with a policy that turns on nationally and outcomes observed monthly, conventional cluster-robust inference is not enough. This is especially true when many claims hinge on p-values around 0.05–0.10. The paper should report **wild-cluster bootstrap p-values** at a minimum, and ideally also randomization/permutation inference over agency-level treatment intensity ranks or top-vs-bottom group assignments. As written, several “findings” may simply not survive appropriate small-cluster inference.

3. **The mechanism is asserted, not shown.**  
   The paper claims that total rulemaking rose because agencies finalized deregulatory rules to earn offset credits, but it never directly estimates effects on **EO 13771 deregulatory vs regulatory designations**, nor on the share of deregulatory actions. That is the most direct empirical implication of the theory. Without that analysis, the interpretation remains speculative. Similarly, the “capacity destruction” claim after rescission is far too strong for a post-2021 negative coefficient with p ≈ 0.09 in one binary specification and no direct staffing or process evidence.

## 4. Suggestions

The project is promising, but I would strongly recommend a substantial refocus around outcomes and design that are closer to the institutional mechanism.

**1. Recenter the paper on composition, not total counts.**  
The most convincing contribution here is not “EO 13771 increased rulemaking,” which is both counterintuitive and weakly supported. It is instead something like: **EO 13771 shifted the composition of rulemaking away from new proposals and toward actions classified as deregulatory, especially at agencies with more economically significant rule portfolios.** That claim is more aligned with the order’s design and more defensible empirically. I would make the EO 13771 designation outcomes central:
- deregulatory actions per agency-period,
- regulatory actions per agency-period,
- deregulatory share,
- ratio of deregulatory to regulatory actions.

Right now the most policy-relevant variable in your data is relegated to the background.

**2. Return to the original duration/completion design or explain clearly why it failed.**  
The manifest’s strongest idea was about whether the regulatory budget changed *processing* of proposed rules: duration, completion, withdrawals. Those are much closer to the concept of bureaucratic constraint than raw counts. If the duration and completion results are null, that is still informative—but then you should say so and build the paper around a null on process plus a shift in composition.  
If you keep the duration analysis, it needs better econometrics. A simple OLS on completed NPRM-final pairs is likely selected: EO 13771 could change which rules ever get finalized, so conditioning on completion induces selection bias. Consider:
- survival/hazard models for time-to-finalization,
- a discrete-time completion model within 1, 2, 3, and 4 years,
- explicit treatment of censoring for later NPRMs,
- withdrawals as a competing risk.

That would make the process side publishable even if effects are modest.

**3. Clarify the mapping from coefficient units to substantive magnitude.**  
At present the paper slides between coefficient scale and real-world effect in a way that is likely to mislead readers. For a continuous treatment DiD, you should report:
- the treatment-intensity distribution,
- effects for a 10 percentage-point increase in intensity,
- effects comparing 75th vs 25th percentile agencies,
- effects for named agencies (e.g., OSHA vs FAA) only if those comparisons are representative.

For example, if the coefficient on log NPRMs is -0.057, and the interquartile range in intensity is, say, 0.10 or 0.15, the implied effect is tiny—on the order of less than 1 percent. If so, the paper should not describe the main continuous-treatment result as a meaningful slowdown. Conversely, if the binary top-vs-bottom comparison gives a 32 percent decline, then the right message is that **nonlinearity is essential** and the continuous linear model masks threshold effects. But then the binary specification cannot be treated as a minor robustness check; it becomes central and needs stronger justification ex ante.

**4. Revisit the agency sample and panel frequency.**  
Why 23 agencies? Why monthly? Those choices seem driven partly by convenience, not by institutional logic. Monthly rule counts at the agency level are noisy, zero-inflated for many agencies, and likely to create substantial serial correlation. Semiannual periods are attractive because:
- the Unified Regulatory Agenda is semiannual,
- agencies often batch actions,
- the treatment is not plausibly operating at true monthly frequency,
- the original manifest already anticipated semester-level analysis.

At a minimum, show that results are similar at monthly, quarterly, and semiannual frequency. Also provide a table listing included and excluded agencies, with docket volumes and treatment intensity. Readers need to know whether sample trimming drives the results.

**5. Use estimators suited to counts and skewness.**  
Log(count+1) TWFE is workable, but it is not obviously ideal here. You have count outcomes with many zeros and a few huge agencies. I would strongly suggest:
- Poisson pseudo-maximum-likelihood with agency and time fixed effects,
- exposure controls if relevant,
- robustness to inverse hyperbolic sine transformations,
- weighting and unweighting by agency size.

The current estimates may be heavily influenced by large agencies such as EPA and FAA. You partly address this by dropping them one at a time, but that is not enough. Show influence diagnostics and maybe leave-one-agency-out plots for the main coefficient.

**6. Fix the event-study interpretation.**  
The paper says the event study confirms flat pre-trends and shows a gradual negative drift. That is not what Table 3 shows. One pre-period coefficient is significant at conventional levels, and the post coefficients bounce in sign with very large standard errors. This is not a clean dynamic pattern. Please present the full event-study figure with confidence intervals and a joint test of pre-trend coefficients, not selected coefficients in a table. Then interpret cautiously. Right now the text overstates what the event study establishes.

**7. Improve the treatment measure and discuss its measurement error.**  
“Economically Significant” share from Regulations.gov is sensible, but it may be measured with error and may not line up perfectly with the rules actually constrained under EO 13771. Independent agencies were exempt; some actions were exempt by statute or category; and significant-rule classifications can be inconsistently populated. You should:
- verify treatment intensity against OIRA/Unified Agenda where possible,
- show whether results change using pre-2017 “significant + economically significant” share,
- possibly use pre-2017 average EO 12866 review intensity if available,
- exclude independent agencies clearly and explain that choice.

The paper currently mixes institutional discussion of significance thresholds with a treatment variable that may be only an imperfect proxy for actual constraint exposure.

**8. Tighten the institutional claims.**  
Some descriptive claims raise concern. For example, the FAA is characterized as mostly routine and therefore lightly constrained, but FAA safety rules can also be consequential; similarly, EPA’s large docket count includes much heterogeneous activity. More broadly, “high-intensity agencies” include CMS at 59 percent, which is strikingly high and deserves validation. I would add an appendix table listing each agency’s pre-2017 intensity and examples of rule types. If those shares are based on small denominators or idiosyncratic coding, the treatment variable may not be credible.

**9. Be much more cautious about “capacity destruction” and “ratchet” language.**  
Those are strong, structural claims. The evidence presented is much weaker: a negative post-rescission coefficient in one specification, with borderline significance, and no direct measurement of staffing, expertise, or attrition. You can say the post-2021 pattern is **consistent with incomplete reversal**, but not that it demonstrates bureaucratic capacity destruction. If you want to keep the ratchet framing, you need better evidence, such as:
- agency staffing or FTE trends in relevant offices,
- retirement/turnover patterns,
- persistence in completion hazards for pre-2021 NPRMs,
- stronger differential post-2021 dynamics concentrated in the most exposed agencies.

**10. Strengthen the placebo design.**  
A placebo at 2013 is not the most informative falsification. Better would be:
- a placebo at January 2017 (inauguration) versus February 2017 (EO implementation),
- pseudo-treatment dates in pre-period years,
- outcomes that should be unaffected, such as clearly exempt actions,
- independent agencies as a comparison group if data permit.

Especially because the main concern is conflating EO 13771 with the Trump transition more generally, the inauguration-versus-EO timing test would be more convincing than a 2013 placebo.

**11. Present a clearer bottom line.**  
An AER: Insights-style paper needs a sharp, credible take-away. Right now there are too many partially supported claims: total activity rose, NPRMs fell, final rules rose, duration did not change, rescission partly reversed, but also maybe not, and maybe there was capacity destruction. I would simplify:
- one primary outcome on composition,
- one process outcome on completion/duration,
- one reversal result,
- one clear mechanism test using EO designation data.

That would make the contribution much easier to understand and assess.

Overall, I like the topic and the underlying data work, and I think there is a publishable paper in this project. But the current draft is not yet there. The main estimates are too fragile to support the current framing, the standard errors are not yet credible for borderline inference, and the strongest direct evidence on composition is not yet brought to bear. A tighter paper, closer to the original mechanism and with more careful inference and magnitude interpretation, would be much stronger.
